60 Degrees Pharmaceuticals, Inc.SXTP

Sixty Degrees Pharmaceuticals, Inc. (NASDAQ-listed but still a micro-cap story) filed its 10-Q for the quarter ended March 31, 2026 with a headline number easy to miss: net product revenues of $162,092. That figure is up 55% year-over-year for Q1 2024 and up 140% for FY2024’s $607,600, so the company’s claim of 65% growth in FY2025 is consistent with its low base and accelerating trajectory. Yet the same filing shows a net loss attributable to the parent of $2.1 million, an operating loss of $2.1 million, and a diluted loss per share of $1.28 on 1.7 million diluted shares. The cash burn rate is not theoretical: net cash used in operating activities was $2.7 million for the quarter. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1946563/000121390026079612/ea0298505-8k_60degrees.htm)

What the company does is sell pharmaceutical products, primarily a repositioned antiviral called AEF01 aimed at influenza and other viral illnesses. According to the company’s clinical pipeline page, AEF01 is under Phase 2 clinical development; there is no evidence of regulatory approvals, commercial launches, or late-stage efficacy data in the supplied filings. The product newsroom highlights FY2025 net product revenues of $1,005,000, a 65% increase versus FY2024’s $607,600, but also notes that the current shelf capacity is exhausted after a $4 million ATM raise. That means the company has monetised its shelf and is now reliant on operations or further financing to fund R&D and working capital. (source: Clinical Pipeline - 60 Degrees Pharmaceuticals, https://60degreespharma.com/clinical-pipeline/; NEWS, https://60degreespharma.com/news/)

The balance sheet itself is compact: total assets of $6.8 million, liabilities of $2.0 million, and stockholders’ equity attributable to the parent of $4.8 million as of March 31, 2026. Cash and cash equivalents were $3.3 million, with short-term investments of $1.2 million reported at December 31, 2025. Research and development expense for the quarter was $281,464, while capital expenditure was a trivial $30,000, underscoring that this is a burn-light, asset-light model focused on clinical development rather than manufacturing scale. Inventory stands at $910,603, with a quarterly change of $2,002-hardly a blockbuster build. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1946563/000121390026079612/ea0298505-8k_60degrees.htm)

The company’s governance story is documented via DEF 14A filed July 2, 2026, which invites votes at www.SXTP.vote and describes directors as having ‘demonstrated business acumen and commitment.’ The same filing notes that ‘certain directors purchased shares’ in an 8-K dated July 20, 2026, a disclosure that may be material to current shareholders given the company’s cash burn profile. The PRE 14A dated June 8, 2026 repeats the governance boilerplate and governance charter URLs, offering no new financial insights but reinforcing the formal side of a board still living in the pre-commercial phase. (source: SXTP DEF 14A, 2026-07-02, https://www.sec.gov/Archives/edgar/data/1946563/000121390026074961/ea0296941-def14a_60degrees.htm; SXTP PRE 14A, 2026-06-08, https://www.sec.gov/Archives/edgar/data/1946563/000121390026066363/ea0292597-pre14a_60degrees.htm; SXTP 8-K, 2026-07-20, https://www.sec.gov/Archives/edgar/data/1946563/000121390026079612/ea0298505-8k_60degrees.htm)

For context on the company’s market presence, the official news page shows a hero image and FY2025 revenue figures but no further disclosure on customer mix, pricing, or market access. The clinical pipeline page lists AEF01 (Phase 2) and other programs, but no Phase 3 readouts, regulatory milestones, or partnership announcements are evidenced in the supplied rail. The absence of late-stage data and commercial scale means the market’s view of Sixty Degrees is still framed by its disclosures, not by realised revenues from a launched drug. (source: NEWS, https://60degreespharma.com/news/; Clinical Pipeline - 60 Degrees Pharmaceuticals, https://60degreespharma.com/clinical-pipeline/)

If you are looking for a chart route, the evidence rail does not supply one; the filing index and company facts JSON confirm the disclosures above but do not include price history, trading volumes, or market-cap data. The company trades on NASDAQ under the symbol SXTP, but the supplied sources do not provide liquidity, spread, or ownership concentration metrics beyond the June 15, 2026 Form 4 filing that lists share counts for insiders. (source: SEC EDGAR filing index, https://www.sec.gov/edgar/browse/?CIK=1946563; SEC submissions JSON, https://data.sec.gov/submissions/CIK0001946563.json; SXTP 4, 2026-06-15, https://www.sec.gov/Archives/edgar/data/1946563/000121390026068853/xslF345X06/ownership.xml)

In short, Sixty Degrees is a micro-cap biotech with a low but growing revenue base, a quarterly cash burn that exceeds revenue, and a clinical pipeline that is early-stage and unaudited. The company’s shelf offering is exhausted, leaving financing, operational execution, or a partnership as the next inflection points. Until then, the story is one of promise, penny-stock optics, and balance-sheet reality that reads like a startup still waiting for its first real product to arrive. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1946563/000121390026079612/ea0298505-8k_60degrees.htm)